<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biomx Inc. — News on 6ix</title>
    <link>https://6ix.com/company/biomx-inc</link>
    <description>Latest news and press releases for Biomx Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 13 Apr 2026 13:20:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/biomx-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d778a951cc36e47533fdf6.webp</url>
      <title>Biomx Inc.</title>
      <link>https://6ix.com/company/biomx-inc</link>
    </image>
    <item>
      <title>BiomX Accelerates Defense Technology Buildout with DFSL Acquisition</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-accelerates-defense-technology-buildout-with-dfsl-acquisition</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-accelerates-defense-technology-buildout-with-dfsl-acquisition</guid>
      <pubDate>Mon, 13 Apr 2026 13:20:00 GMT</pubDate>
      <description>Acquisition expands BiomX’s defense portfolio with aligned capabilities designed to integrate across detection, analysis, and response, reinforcing its position in AI-enabled security systemsNETANYA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE: PHGE) (“BiomX&quot; or the “Company&quot;) today announced that it has accelerated the exercise of its previously disclosed exclusive option and entered into a definitive agreement to acquire a controlling interest in DFSL, an Israeli defense engine</description>
    </item>
    <item>
      <title>BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-acquires-zorronet-autonomous-ai-command-and-control-platform-for-real-time-defense-and-security-applications</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-acquires-zorronet-autonomous-ai-command-and-control-platform-for-real-time-defense-and-security-applications</guid>
      <pubDate>Fri, 10 Apr 2026 12:30:00 GMT</pubDate>
      <description>Targets $81B command-and-control and video analytics markets by 2030, driven by real-time situational awareness in defense environmentsNETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This acquisition marks BiomX’s entry into the defense, security and rescue sector and establishes a foundation for building a diversified port</description>
    </item>
    <item>
      <title>BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-obtains-option-to-acquire-control-of-israeli-laser-radar-counter-drone-system-2</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-obtains-option-to-acquire-control-of-israeli-laser-radar-counter-drone-system-2</guid>
      <pubDate>Tue, 31 Mar 2026 14:48:00 GMT</pubDate>
      <description>The platform delivers ~99% accuracy in real-world deployments across defense and infrastructure; When closed, the transaction value is estimated at approximately $45 millionNETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary LADAR (Laser Radar)–based detection systems for security, defense, and critical infrastructure applications. DFSL’s LADAR tech</description>
    </item>
    <item>
      <title>BiomX Adds Former Mossad Deputy to Advisory Board</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-adds-former-mossad-deputy-to-advisory-board</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-adds-former-mossad-deputy-to-advisory-board</guid>
      <pubDate>Mon, 30 Mar 2026 13:28:00 GMT</pubDate>
      <description>Dr. Ehud (Udi) Levi brings decades of intelligence experience as Company evaluates expansion into security, defense, and counter-UAS technologiesNETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board. Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems,</description>
    </item>
    <item>
      <title>BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders&apos; Equity Deficiency</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-inc-received-nyse-american-notification-letter-regarding-stockholders-equity-deficiency</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-inc-received-nyse-american-notification-letter-regarding-stockholders-equity-deficiency</guid>
      <pubDate>Fri, 27 Mar 2026 20:30:00 GMT</pubDate>
      <description>Discloses “Going Concern” Explanatory Paragraph in Auditor’s ReportNETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the “NYSE American”) that the Company was not in compliance with the NYSE American’s continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the “Company Guide”), requir</description>
    </item>
    <item>
      <title>BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-launches-security-subsidiary-in-israel-and-will-initially-invest-over-dollar3-million-in-its-operations</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-launches-security-subsidiary-in-israel-and-will-initially-invest-over-dollar3-million-in-its-operations</guid>
      <pubDate>Thu, 26 Mar 2026 12:48:00 GMT</pubDate>
      <description>Initiative marks entry into Israel’s rapidly growing autonomous AI defense, firefighting and first response activitiesNETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced the launch of X Security &amp; Defense LTD., a new wholly-owned subsidiary. The company will finance its 2026 operations with over $3 million from internal funds, including for operations and acquisitions related to security, defense and first response. For its initial transaction, Bi</description>
    </item>
    <item>
      <title>BiomX CEO Issues Letter to Stockholders</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-ceo-issues-letter-to-stockholders</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-ceo-issues-letter-to-stockholders</guid>
      <pubDate>Thu, 19 Mar 2026 13:15:00 GMT</pubDate>
      <description>BiomX Inc. (NYSE American: PHGE), today released the following letter from its Chief Executive Officer to stockholders.</description>
    </item>
    <item>
      <title>BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-names-michael-oster-as-chief-executive-officer-david-rokach-chief-financial-officer-to-support-next-phase-of-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-names-michael-oster-as-chief-executive-officer-david-rokach-chief-financial-officer-to-support-next-phase-of-growth</guid>
      <pubDate>Mon, 09 Mar 2026 13:00:00 GMT</pubDate>
      <description>BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer.</description>
    </item>
    <item>
      <title>BiomX Issues Statement Regarding Recent Common Stock Trading Activity</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-issues-statement-regarding-recent-common-stock-trading-activity</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-issues-statement-regarding-recent-common-stock-trading-activity</guid>
      <pubDate>Tue, 27 Jan 2026 18:41:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that wou</description>
    </item>
    <item>
      <title>BiomX Announces $3.0 Million Private Placement</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-announces-dollar30-million-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-announces-dollar30-million-private-placement</guid>
      <pubDate>Mon, 29 Dec 2025 13:00:00 GMT</pubDate>
      <description>Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic AlternativesNESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placemen</description>
    </item>
    <item>
      <title>BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-announces-discontinuation-of-phase-2b-bx004-trial-following-internal-review</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-announces-discontinuation-of-phase-2b-bx004-trial-following-internal-review</guid>
      <pubDate>Mon, 08 Dec 2025 12:30:00 GMT</pubDate>
      <description>Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE)</description>
    </item>
    <item>
      <title>BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-provides-update-on-bx004-phase-2b-trial-in-cystic-fibrosis</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-provides-update-on-bx004-phase-2b-trial-in-cystic-fibrosis</guid>
      <pubDate>Tue, 25 Nov 2025 21:40:00 GMT</pubDate>
      <description>The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosing Following the DMC review, the study protocol will be updated, and topline results</description>
    </item>
    <item>
      <title>BiomX Inc. Announces 1-for-19 Reverse Stock Split</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-inc-announces-1-for-19-reverse-stock-split</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-inc-announces-1-for-19-reverse-stock-split</guid>
      <pubDate>Fri, 14 Nov 2025 21:31:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it intends to effect a one-for-nineteen reverse split (the &quot;Reverse Stock Split&quot;) of the Company’s common stock (the &quot;Common Stock&quot;). The Common Stock will continue to trade on the NYSE American under the existing symbol “PHGE” and will begin t</description>
    </item>
    <item>
      <title>BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-reports-third-quarter-2025-financial-results-and-provides-program-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-reports-third-quarter-2025-financial-results-and-provides-program-updates</guid>
      <pubDate>Wed, 12 Nov 2025 12:30:00 GMT</pubDate>
      <description>Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company’s prior Phase 2 success BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZION</description>
    </item>
    <item>
      <title>BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-to-report-third-quarter-2025-financial-results-and-program-updates-on-november-12-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-to-report-third-quarter-2025-financial-results-and-program-updates-on-november-12-2025</guid>
      <pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its third quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and a live audio webcast at 8:30 a.m. ET, to di</description>
    </item>
    <item>
      <title>BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-announces-positive-fda-feedback-supporting-next-generation-phage-cocktail-program-for-diabetic-foot-infections</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-announces-positive-fda-feedback-supporting-next-generation-phage-cocktail-program-for-diabetic-foot-infections</guid>
      <pubDate>Tue, 04 Nov 2025 13:40:00 GMT</pubDate>
      <description>New FDA feedback confirms clinical pathway for fixed multi-phage cocktail BX011, expanding development into diabetic foot infections (DFI) and unlocking a major commercial opportunityNESS ZIONA, Israel, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has received positive feedback from the U.S. Food and Drug</description>
    </item>
    <item>
      <title>BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-provides-a-program-update-and-announces-new-fda-feedback-potentially-expanding-bx004-development-pathways</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-provides-a-program-update-and-announces-new-fda-feedback-potentially-expanding-bx004-development-pathways</guid>
      <pubDate>Fri, 17 Oct 2025 12:30:00 GMT</pubDate>
      <description>BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed In parallel, new written FDA feedback underscores the significant unmet need BiomX is addressing and outlines new potential development approaches European enrollment and dosing remain strong; Phase 2b study remains on track to report topline resul</description>
    </item>
    <item>
      <title>BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-ceo-to-present-at-hc-wainwright-27th-annual-global-investment-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-ceo-to-present-at-hc-wainwright-27th-annual-global-investment-conference</guid>
      <pubDate>Thu, 04 Sep 2025 12:30:00 GMT</pubDate>
      <description>Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company advancing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, the Company’s Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference ta</description>
    </item>
    <item>
      <title>BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-provides-update-on-bx004-phase-2b-trial-for-the-treatment-of-patients-with-cystic-fibrosis</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-provides-update-on-bx004-phase-2b-trial-for-the-treatment-of-patients-with-cystic-fibrosis</guid>
      <pubDate>Tue, 19 Aug 2025 12:19:00 GMT</pubDate>
      <description>U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification regarding the BX004 drug candidate Enrollment and dosing of patients outside the US is continuing in accordance with protocol NESS ZIONA, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engi</description>
    </item>
    <item>
      <title>BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates</title>
      <link>https://6ix.com/company/biomx-inc/news/biomx-reports-second-quarter-2025-financial-results-and-provides-program-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/biomx-inc/news/biomx-reports-second-quarter-2025-financial-results-and-provides-program-updates</guid>
      <pubDate>Wed, 13 Aug 2025 10:30:00 GMT</pubDate>
      <description>Positive Phase 2 results for BX211 demonstrated &gt;40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of new BX004 Phase 1b/2a data demonstrated further ~500-fold (2.7 log₁₀)2 bacterial reduction versus placebo with no detectable emergence of resistance observed, highlighting strength of BiomX platform capabilitiesPhase 2b trial of BX004 in Cystic Fibrosis (CF) has successfully commenc</description>
    </item>
  </channel>
</rss>